Core Viewpoint - The stock of Innovent Biologics (01801) rose nearly 3% following the announcement that its drug IBI3003 received Fast Track Designation from the FDA for treating relapsed or refractory multiple myeloma [1] Group 1: Company Developments - Innovent Biologics' IBI3003 is a tri-specific antibody targeting GPRC5D/BCMA/CD3, which is currently undergoing Phase I/II clinical trials in China, Australia, and the United States [1] - The FDA's Fast Track Designation is aimed at patients who have undergone at least four lines of treatment, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody [1] Group 2: Market Reaction - As of the report, Innovent Biologics' stock price increased by 2.2%, reaching 83.6 HKD, with a trading volume of 204 million HKD [1]
港股异动 | 信达生物(01801)涨近3% IBI3003获美国FDA快速通道资格认定 治疗多发性骨髓瘤